Eledon Pharmaceuticals, Inc. (ELDN)
2.93
-0.06
(-2.01%)
USD |
NASDAQ |
Sep 03, 16:00
2.91
-0.02
(-0.68%)
After-Hours: 05:01
Eledon Pharmaceuticals Research and Development Expense (Annual) : 66.27M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 66.27M |
| December 31, 2024 | 51.96M |
| December 31, 2023 | 30.31M |
| December 31, 2022 | 27.08M |
| December 31, 2021 | 23.74M |
| December 31, 2020 | 6.131M |
| December 31, 2019 | 8.128M |
| Date | Value |
|---|---|
| December 31, 2018 | 6.817M |
| December 31, 2017 | 2.022M |
| December 31, 2016 | 3.191M |
| December 31, 2015 | 32.64M |
| December 31, 2014 | 14.58M |
| December 31, 2013 | 12.20M |
| December 31, 2012 | 7.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Viking Therapeutics, Inc. | 344.96M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |